Hyaluronan, Inflammation, and Breast Cancer Progression.

Kathryn L Schwertfeger, Mary K Cowman, Patrick G Telmer, Eva A Turley, James B McCarthy
Author Information
  1. Kathryn L Schwertfeger: Department of Laboratory Medicine and Pathology, Masonic Comprehensive Cancer Center, University of Minnesota , Minneapolis, MN , USA.
  2. Mary K Cowman: Biomatrix Research Center, Department of Chemical and Biomolecular Engineering, New York University Polytechnic School of Engineering , New York, NY , USA.
  3. Patrick G Telmer: Department of Oncology, London Health Science Center, Schulich School of Medicine, Western University , London, ON , Canada ; Department of Biochemistry and Surgery, London Health Science Center, Schulich School of Medicine, Western University , London, ON , Canada.
  4. Eva A Turley: Department of Oncology, London Health Science Center, Schulich School of Medicine, Western University , London, ON , Canada ; Department of Biochemistry and Surgery, London Health Science Center, Schulich School of Medicine, Western University , London, ON , Canada.
  5. James B McCarthy: Department of Laboratory Medicine and Pathology, Masonic Comprehensive Cancer Center, University of Minnesota , Minneapolis, MN , USA.

Abstract

Breast cancer-induced inflammation in the tumor reactive stroma supports invasion and malignant progression and is contributed to by a variety of host cells including macrophages and fibroblasts. Inflammation appears to be initiated by tumor cells and surrounding host fibroblasts that secrete pro-inflammatory cytokines and chemokines and remodel the extracellular matrix (ECM) to create a pro-inflammatory "cancerized" or tumor reactive microenvironment that supports tumor expansion and invasion. The tissue polysaccharide hyaluronan (HA) is an example of an ECM component within the cancerized microenvironment that promotes breast cancer progression. Like many ECM molecules, the function of native high-molecular weight HA is altered by fragmentation, which is promoted by oxygen/nitrogen free radicals and release of hyaluronidases within the tumor microenvironment. HA fragments are pro-inflammatory and activate signaling pathways that promote survival, migration, and invasion within both tumor and host cells through binding to HA receptors such as CD44 and RHAMM/HMMR. In breast cancer, elevated HA in the peri-tumor stroma and increased HA receptor expression are prognostic for poor outcome and are associated with disease recurrence. This review addresses the critical issues regarding tumor-induced inflammation and its role in breast cancer progression focusing specifically on the changes in HA metabolism within tumor reactive stroma as a key factor in malignant progression.

Keywords

References

  1. J Cancer Res Clin Oncol. 2010 May;136(5):745-50 [PMID: 19898865]
  2. Traffic. 2014 May;15(5):500-15 [PMID: 24502338]
  3. Nat Rev Cancer. 2004 Jul;4(7):528-39 [PMID: 15229478]
  4. Clin Cancer Res. 2009 Dec 15;15(24):7462-7468 [PMID: 20008845]
  5. J Pathol. 2012 Jan;226(2):148-57 [PMID: 21989643]
  6. Am J Pathol. 2012 Oct;181(4):1250-70 [PMID: 22889846]
  7. J Biol Chem. 2004 Jun 11;279(24):25745-54 [PMID: 15060082]
  8. Ann Rheum Dis. 1991 Jun;50(6):389-92 [PMID: 1711835]
  9. J Biol Chem. 1997 May 30;272(22):13997-4000 [PMID: 9206724]
  10. Breast Cancer Res. 2012 May 23;14(3):R84 [PMID: 22621373]
  11. Front Immunol. 2015 Mar 23;6:123 [PMID: 25852691]
  12. Int J Cancer. 1997 Nov 4;73(3):327-31 [PMID: 9359477]
  13. Chin Med J (Engl). 2009 Jun 5;122(11):1300-4 [PMID: 19567141]
  14. Int J Oncol. 2003 Aug;23(2):269-84 [PMID: 12851675]
  15. Cancer Cell. 2012 Mar 20;21(3):418-29 [PMID: 22439937]
  16. Trends Immunol. 2001 Jun;22(6):317-21 [PMID: 11377291]
  17. Cancer. 1997 Aug 1;80(3):421-34 [PMID: 9241076]
  18. Exp Cell Res. 2009 Jul 1;315(11):1914-23 [PMID: 19285976]
  19. Breast Cancer Res Treat. 2014 Jan;143(2):277-86 [PMID: 24337597]
  20. Int J Cancer. 2013 Feb 1;132(3):531-9 [PMID: 22753277]
  21. PLoS One. 2014 Feb 13;9(2):e88479 [PMID: 24551108]
  22. J Immunol. 2007 Jul 15;179(2):744-7 [PMID: 17617562]
  23. J Clin Invest. 1993 Jun;91(6):2368-77 [PMID: 8514850]
  24. J Inflamm (Lond). 2008 Nov 05;5:20 [PMID: 18986521]
  25. Oncol Lett. 2012 Jan;3(1):147-154 [PMID: 22740871]
  26. Biol Open. 2015 Mar 06;4(4):562-71 [PMID: 25750434]
  27. Histopathology. 2014 Sep;65(3):328-39 [PMID: 24527698]
  28. Nature. 2013 Jul 18;499(7458):346-9 [PMID: 23783513]
  29. Front Physiol. 2014 Mar 05;5:75 [PMID: 24634660]
  30. FASEB J. 2015 Apr;29(4):1290-8 [PMID: 25550464]
  31. Cancer. 2014 Jun 15;120(12):1800-9 [PMID: 24668563]
  32. J Pathol. 2001 Sep;195(2):191-6 [PMID: 11592098]
  33. PLoS One. 2014 Dec 12;9(12):e115103 [PMID: 25501357]
  34. Am J Respir Cell Mol Biol. 2005 Nov;33(5):447-54 [PMID: 16037485]
  35. J Cell Biol. 2006 Dec 18;175(6):1017-28 [PMID: 17158951]
  36. Front Immunol. 2015 Jun 02;6:261 [PMID: 26082778]
  37. J Histochem Cytochem. 2007 Dec;55(12):1191-8 [PMID: 17827165]
  38. J Pathol. 2006 May;209(1):67-77 [PMID: 16482496]
  39. Nature. 2002 Dec 19-26;420(6917):860-7 [PMID: 12490959]
  40. Gut. 2013 Jan;62(1):112-20 [PMID: 22466618]
  41. Matrix Biol. 2012 Mar;31(2):90-100 [PMID: 22155153]
  42. J Transl Med. 2014 Nov 29;12:322 [PMID: 25432242]
  43. J Biol Chem. 2001 Jun 1;276(22):19420-30 [PMID: 11278811]
  44. Inflammation. 1993 Aug;17(4):403-15 [PMID: 8406685]
  45. Cell Death Dis. 2013 Oct 03;4:e819 [PMID: 24091662]
  46. J Biol Chem. 2007 Jul 6;282(27):19426-41 [PMID: 17493932]
  47. Cancer Discov. 2011 Jun;1(1):54-67 [PMID: 22039576]
  48. Histochem Cell Biol. 2015 May;143(5):531-43 [PMID: 25511416]
  49. J Exp Clin Cancer Res. 2010 Jul 10;29:92 [PMID: 20618976]
  50. J Biol Chem. 2004 Aug 6;279(32):33281-9 [PMID: 15190064]
  51. PLoS One. 2011;6(7):e22836 [PMID: 21829529]
  52. J Exp Med. 2000 Sep 18;192(6):769-79 [PMID: 10993908]
  53. Physiol Rev. 2011 Jan;91(1):221-64 [PMID: 21248167]
  54. J Biol Chem. 2012 Dec 14;287(51):43094-107 [PMID: 23118219]
  55. Int J Cancer. 2007 Jun 15;120(12):2557-67 [PMID: 17315194]
  56. Clin Cancer Res. 2004 Nov 1;10(21):7144-9 [PMID: 15534085]
  57. Genomics. 1997 May 1;41(3):493-7 [PMID: 9169154]
  58. Int J Cancer. 2011 Mar 15;128(6):1303-15 [PMID: 20473947]
  59. Oncol Rep. 2013 Jan;29(1):335-42 [PMID: 23124556]
  60. Cancer Res. 2010 Apr 1;70(7):2613-23 [PMID: 20332231]
  61. Biochem Pharmacol. 2010 Aug 15;80(4):480-90 [PMID: 20435021]
  62. Eur J Cell Biol. 2006 Aug;85(8):699-715 [PMID: 16822580]
  63. Histopathology. 2015 May;66(6):873-83 [PMID: 25387851]
  64. Oncol Rep. 1999 Jan-Feb;6(1):65-70 [PMID: 9864403]
  65. J Biol Chem. 2007 Jun 1;282(22):16667-80 [PMID: 17392272]
  66. Eur J Cancer. 2010 May;46(7):1271-7 [PMID: 20303742]
  67. Mol Cell Biol. 2007 Jan;27(2):595-604 [PMID: 17101772]
  68. Clin Cancer Res. 2008 Feb 15;14(4):1274-80 [PMID: 18281563]
  69. Innate Immun. 2013 Oct;19(5):462-78 [PMID: 23283732]
  70. Am J Pathol. 2000 Feb;156(2):529-36 [PMID: 10666382]
  71. J Biochem. 2013 Nov;154(5):395-408 [PMID: 24092768]
  72. Blood. 2007 Jul 15;110(2):587-95 [PMID: 17395778]
  73. Clin Invest Med. 2011 Feb 01;34(1):E45-54 [PMID: 21291635]
  74. J Biol Chem. 2012 Oct 26;287(44):37406-19 [PMID: 22948158]
  75. Arch Biochem Biophys. 1997 May 15;341(2):245-50 [PMID: 9169011]
  76. J Biol Chem. 2010 Apr 2;285(14):10724-35 [PMID: 19887450]
  77. J Biol Chem. 1997 Mar 21;272(12):8013-8 [PMID: 9065473]
  78. Trends Immunol. 2012 Mar;33(3):119-26 [PMID: 22277903]
  79. Br J Cancer. 2013 Sep 17;109(6):1556-61 [PMID: 24002601]
  80. J Pathol. 2002 Mar;196 (3):254-65 [PMID: 11857487]
  81. J Biol Chem. 1998 May 1;273(18):11342-8 [PMID: 9556628]
  82. Mol Cancer Res. 2012 Oct;10(10):1294-305 [PMID: 22893608]
  83. Adv Cancer Res. 2014;123:211-29 [PMID: 25081531]
  84. Biomed Res Int. 2014;2014:103923 [PMID: 25157350]
  85. Sci Rep. 2014 Jul 18;4:5750 [PMID: 25034888]
  86. Nat Rev Cancer. 2004 Jan;4(1):71-8 [PMID: 14708027]
  87. J Biol Chem. 2011 Jul 22;286(29):25675-86 [PMID: 21596748]
  88. Anal Biochem. 2015 Apr 1;474:78-88 [PMID: 25579786]
  89. J Immunol. 2008 Nov 15;181(10):7044-54 [PMID: 18981124]
  90. J Cell Sci. 1999 Nov;112 ( Pt 22):3943-54 [PMID: 10547355]
  91. Ciba Found Symp. 1989;143:187-201; discussion 201-7, 281-5 [PMID: 2478344]
  92. Cancer Res. 2012 Jan 15;72(2):537-47 [PMID: 22113945]
  93. Int J Cancer. 2002 Oct 10;101(5):415-22 [PMID: 12216068]
  94. Front Biosci. 2007 Jan 01;12:1574-85 [PMID: 17127404]
  95. J Biol Chem. 2013 May 31;288(22):16085-97 [PMID: 23589310]
  96. J Immunol. 2008 Feb 15;180(4):2011-7 [PMID: 18250403]
  97. PLoS One. 2011;6(9):e25661 [PMID: 21984937]
  98. J Cell Biol. 1999 Feb 22;144(4):789-801 [PMID: 10037799]
  99. J Biol Chem. 2010 Aug 6;285(32):24639-45 [PMID: 20522558]
  100. J Leukoc Biol. 2005 Nov;78(5):1043-51 [PMID: 16204623]
  101. J Exp Med. 1996 Apr 1;183(4):1663-8 [PMID: 8666924]
  102. Biomed Res Int. 2013;2013:929531 [PMID: 24083250]
  103. Annu Rev Cell Dev Biol. 2007;23:435-61 [PMID: 17506690]
  104. Clin Cancer Res. 2013 Feb 1;19(3):643-56 [PMID: 23149820]
  105. BMC Cancer. 2012 Oct 06;12:458 [PMID: 23039365]
  106. Med Oncol. 2015 Feb;32(2):352 [PMID: 25572805]
  107. FEBS Lett. 2006 Nov 13;580(26):6259-68 [PMID: 17070806]
  108. J Cell Sci. 2008 Apr 1;121(Pt 7):925-32 [PMID: 18354082]
  109. Glycobiology. 2012 Mar;22(3):400-10 [PMID: 22038477]
  110. J Biomed Mater Res A. 2014 Feb;102(2):305-14 [PMID: 23533059]
  111. J Biol Chem. 2011 Dec 9;286(49):42349-59 [PMID: 22016393]
  112. J Biol Chem. 1998 Aug 28;273(35):22466-70 [PMID: 9712871]
  113. PLoS One. 2012;7(3):e33142 [PMID: 22427969]
  114. Cancer Res. 2014 Jan 1;74(1):374-86 [PMID: 24197137]
  115. Cell. 2006 Jan 27;124(2):263-6 [PMID: 16439202]
  116. Cytokine Growth Factor Rev. 2006 Oct;17(5):325-37 [PMID: 16931107]
  117. Front Biosci. 2008 Jan 01;13:453-61 [PMID: 17981560]
  118. Cancer Discov. 2011 Sep;1(4):291-6 [PMID: 22053288]
  119. Cell. 2010 Apr 2;141(1):39-51 [PMID: 20371344]
  120. FEBS J. 2011 May;278(9):1419-28 [PMID: 21362137]
  121. J Immunol. 2006 Jan 1;176(1):284-90 [PMID: 16365420]
  122. Oncoimmunology. 2013 Feb 1;2(2):e22945 [PMID: 23526132]
  123. Am J Pathol. 2007 Mar;170(3):1086-99 [PMID: 17322391]
  124. Blood. 2006 Mar 1;107(5):1761-7 [PMID: 16269611]
  125. Int J Cancer. 2012 Jan 15;130(2):454-66 [PMID: 21387290]
  126. Neuro Endocrinol Lett. 2009;30 Suppl 1:106-11 [PMID: 20027154]
  127. J Biol Chem. 2010 Nov 19;285(47):36721-35 [PMID: 20843787]
  128. Cancer Lett. 2010 Dec 8;298(2):238-49 [PMID: 20688428]
  129. J Cell Sci. 2003 May 15;116(Pt 10):1863-73 [PMID: 12692188]
  130. IUBMB Life. 2002 Oct;54(4):195-9 [PMID: 12512858]

Grants

  1. R01 CA132827/NCI NIH HHS

Word Cloud

Created with Highcharts 10.0.0tumorHAprogressionmicroenvironmentwithinbreastcancerinflammationreactivestromainvasionhostcellspro-inflammatoryECMBreastsupportsmalignantfibroblastsInflammationhyaluronanCD44RHAMM/HMMRcancer-inducedcontributedvarietyincludingmacrophagesappearsinitiatedsurroundingsecretecytokineschemokinesremodelextracellularmatrixcreate"cancerized"expansiontissuepolysaccharideexamplecomponentcancerizedpromotesLikemanymoleculesfunctionnativehigh-molecularweightalteredfragmentationpromotedoxygen/nitrogenfreeradicalsreleasehyaluronidasesfragmentsactivatesignalingpathwayspromotesurvivalmigrationbindingreceptorselevatedperi-tumorincreasedreceptorexpressionprognosticpooroutcomeassociateddiseaserecurrencereviewaddressescriticalissuesregardingtumor-inducedrolefocusingspecificallychangesmetabolismkeyfactorHyaluronanCancerProgressionmacrophage

Similar Articles

Cited By